Although immunotherapies and selective inhibitors of the BRAF/MEK/ERK pathway have improved outcomes for patients with advanced melanoma, the majority of melanomas either are intrinsically resistant or develop resistance after initial response [1–3]. This evidence concerns the gene MAPK1 and melanoma.